title: [Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation].
abstract: Objective:To evaluate the efficacy and safety of eltrombopag in post-HSCT thrombocytopenia.Methods:A total of 10 patients who underwent post-HSCT thrombocytopenia at Peking University center, who had been treated with eltrombopag, were retrospectively evaluated.Results:Of the 10 cases, 5 males and 5 females with a median of 34 years old (range, 17-54 years), 5 patients were acute myeloid leukemia, 3 with acute lymphoid leukemia and 2 with severe aplastic anemia. Nine patients had undergone haplo-identical donor transplantation, and one patient was a matched related recipient. All patients had failed prior treatment for thrombocytopenia before eltrombopag started. The median time when eltrombopag started was 221 days (range, 73-917 days) after transplantation. Five patients (50%) had achieved CR. The cumulative incidence of 30-day CR was 35.7%. The median time to platelet recovery ≥ 50 × 109/L without transfusion support was 16 days (range, 10-56 days). At the last follow-up, three of the patients with CR had withdrawal eltrombopag and remained normal platelet counts. No patients experienced drug-related adverse events.Conclusion:Eltrombopag is effective and well tolerated in patients with refractory post-HSCT thrombocytopenia.
authors.affiliation: Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Y R
authors.initials: YR
authors.lastname: Ma
authors.forename: X J
authors.initials: XJ
authors.lastname: Huang
authors.forename: X D
authors.initials: XD
authors.lastname: Mo
authors.forename: W
authors.initials: W
authors.lastname: Han
authors.forename: C H
authors.initials: CH
authors.lastname: Yan
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Ji
authors.forename: Y Y
authors.initials: YY
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: X H
authors.initials: XH
authors.lastname: Zhang
authors.forename: K Y
authors.initials: KY
authors.lastname: Liu
authors.forename: L P
authors.initials: LP
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D001565:Benzoates / Q000627:therapeutic use*; D001792:Blood Platelets; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy; D017713:Platelet Transfusion; D011720:Pyrazoles / Q000627:therapeutic use*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000188:drug therapy*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; C520809:eltrombopag